-
FDA approves first CGM system with implantable sensor, mobile app
The U.S. Food and Drug Administration has approved the Eversense Continuous Glucose Monitoring system for use in adults with diabetes, marking the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to 90 days.
-
FDA expands approval of diabetes management device for younger pediatric patients
The U.S. Food and Drug Administration has expanded the approval of the MiniMed 670G hybrid closed looped system, a diabetes management device that is intended to automatically monitor glucose and provide appropriate basal insulin doses with little or no input from the user, to include individuals aged 7 to 13 with type 1 diabetes.
